Hormonal
Obesity (BMI ≥30 kg/m²) is a major risk factor for the development, recurrence, and mortality of several solid-organ and hematological malignancies, including post-menopausal breast, colorectal, endometrial, kidney, esophageal, pancreatic, liver, and gallbladder cancers.
Maintaining a healthy body weight (BMI <25) is a critical strategy for reducing the risk of developing several common cancers, particularly post-menopausal breast, colorectal, and endometrial cancers. For cancer survivors, weight management is essential to reduce the risk of recurrence and improve survival outcomes.
Obesity is a risk factor for several major cancers, including post-menopausal breast, colorectal, endometrial, kidney, esophageal, pancreatic, liver, and gallbladder cancer.
Why this rating
Based on large population-based studies (5.24 million individuals), Mendelian randomization, and umbrella reviews of systematic reviews.
Source
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Sukanya Pati et al. · Cancers · 2023
DOI 10.3390/cancers15020485
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →